- Home
- CMMB vs MDAI Comparison
CMMB vs MDAI Comparison
Compare CMMB & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- MDAI
- Stock Information
- Founded
- CMMB 2004
- MDAI 2013
- Country
- CMMB Israel
- MDAI United States
- Employees
- CMMB N/A
- MDAI N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- MDAI Medical/Dental Instruments
- Sector
- CMMB Health Care
- MDAI Health Care
- Exchange
- CMMB Nasdaq
- MDAI Nasdaq
- Market Cap
- CMMB 27.0M
- MDAI 23.8M
- IPO Year
- CMMB N/A
- MDAI N/A
- Fundamental
- Price
- CMMB $1.60
- MDAI $1.14
- Analyst Decision
- CMMB Strong Buy
- MDAI Strong Buy
- Analyst Count
- CMMB 3
- MDAI 3
- Target Price
- CMMB $7.33
- MDAI $4.50
- AVG Volume (30 Days)
- CMMB 119.1K
- MDAI 587.1K
- Earning Date
- CMMB 11-14-2024
- MDAI 11-06-2024
- Dividend Yield
- CMMB N/A
- MDAI N/A
- EPS Growth
- CMMB N/A
- MDAI N/A
- EPS
- CMMB N/A
- MDAI N/A
- Revenue
- CMMB N/A
- MDAI $27,264,000.00
- Revenue This Year
- CMMB N/A
- MDAI $59.53
- Revenue Next Year
- CMMB N/A
- MDAI N/A
- P/E Ratio
- CMMB N/A
- MDAI N/A
- Revenue Growth
- CMMB N/A
- MDAI 44.52
- 52 Week Low
- CMMB $0.42
- MDAI $0.82
- 52 Week High
- CMMB $2.55
- MDAI $3.72
- Technical
- Relative Strength Index (RSI)
- CMMB 52.53
- MDAI 40.97
- Support Level
- CMMB $1.54
- MDAI $1.35
- Resistance Level
- CMMB $1.73
- MDAI $1.58
- Average True Range (ATR)
- CMMB 0.16
- MDAI 0.18
- MACD
- CMMB 0.01
- MDAI -0.04
- Stochastic Oscillator
- CMMB 45.45
- MDAI 22.03
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.